Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 07, 2020 07:00 ET | Source: IN8bio, Inc

IN8bio Appoints Alan S. Roemer as Chairman

NEW YORK, Oct. 07, 2020 (GLOBE NEWSWIRE) -- IN8bio, Inc., a clinical-stage biotechnology company focused on developing innovative allogeneic, autologous and genetically modified gamma-delta T cell...
September 17, 2020 07:00 ET | Source: IN8bio, Inc.

IN8bio Names Kate Rochlin, PhD Assistant Vice President Operations and Innovation

NEW YORK, Sept. 17, 2020 (GLOBE NEWSWIRE) -- IN8bio, Inc., a clinical-stage biotechnology company focused on developing innovative therapies for the treatment of cancers, including solid tumors, by...
August 24, 2020 07:00 ET | Source: IN8bio, Inc.

Incysus Therapeutics Announces Name Change to IN8bio, Inc.

NEW YORK, Aug. 24, 2020 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on delivering innovative gamma-delta (γδ) T cell immunotherapies for the...
August 07, 2020 08:35 ET | Source: Incysus Therapeutics, Inc.

Incysus Therapeutics to Present at Solebury Trout Private Company Showcase

NEW YORK, Aug. 07, 2020 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a clinical-stage biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell...
August 03, 2020 07:00 ET | Source: Incysus Therapeutics, Inc.

Incysus Therapeutics to Present at LifeSci Partners Summer Symposium

NEW YORK, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a clinical-stage biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell...
June 02, 2020 07:00 ET | Source: Incysus Therapeutics, Inc.

First Patient Treated in Phase 1 Clinical Trial Of Incysus Therapeutics Gamma Delta (γδ) T Cell Immunotherapy for Patients With Newly Diagnosed Glioblastoma

NEW YORK, June 02, 2020 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
May 28, 2020 07:00 ET | Source: Incysus Therapeutics, Inc.

Incysus Therapeutics Announces Poster Presentation at the 2020 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting

NEW YORK, May 28, 2020 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
May 12, 2020 07:00 ET | Source: Incysus Therapeutics, Inc.

Incysus Therapeutics Treats First Patient in Phase 1 Study of Gamma Delta (γδ) T Cell Immunotherapy in Leukemia and Lymphoma Patients Undergoing Allogeneic Stem Cell Transplantation

NEW YORK, May 12, 2020 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
April 06, 2020 07:00 ET | Source: Incysus Therapeutics, Inc.

INCYSUS THERAPEUTICS TO PRESENT AT THE 2020 SOLEBURY TROUT VIRTUAL INVESTOR CONFERENCE

NEW YORK, April 06, 2020 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a clinical-stage biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell...
March 31, 2020 07:00 ET | Source: Incysus Therapeutics, Inc.

INCYSUS THERAPEUTICS TO PRESENT AT THE NYC SPRING ONCOLOGY INVESTOR CONFERENCE

NEW YORK, March 31, 2020 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a clinical-stage biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell...